CardiacAssist's new TandemLung oxygenator receives FDA clearance

NewsGuard 100/100 Score

CardiacAssist, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for its new TandemLung® oxygenator, a medical device that acts as an artificial lung to infuse oxygen and remove carbon dioxide from the blood. When paired with CardiacAssist's TandemHeart® blood pump, the TandemLung represents a leap forward in extracorporeal life support (ECLS) technology for patients in need of critical cardiopulmonary care.

Every year in North America, more than 300,000 patients experience an acute cardiac or respiratory event that requires emergency intervention. However, historically only a small percentage of these patients have received advanced life support utilizing products like the TandemHeart and TandemLung, primarily due to the complexity of deploying existing technology to perform such procedures. The TandemLung oxygenator was developed to make ECLS faster and more accessible with a design optimized for simplicity and performance. Its low priming volume and patent-protected radial flow technology allow the device to be deployed quickly to protect patients from the negative effects of diminished cardiac or respiratory function.

"After our original TandemHeart pump was cleared for use with an oxygenator in 2011, our team immediately began working with experts in the field to understand how to reduce the complexity of cardiopulmonary bypass technology so that more patients could receive this potentially life-saving procedure," said John Marous, President and CEO of CardiacAssist. "The design of the TandemLung is a direct result of those efforts. This release represents our 6th new product clearance since September 2013, and we are proud to dedicate ourselves to improving the lives of patients by delivering innovative, easy-to-use devices for simplified life support."

Adult ECLS has grown from less than 100 procedures per year in the 1990's to more than 3,000 procedures per year in 2015, and today it comprises the most rapidly growing segment of the circulatory support industry. Healthcare professionals and hospitals can now turn to CardiacAssist as a premier, single-source provider of a comprehensive circulatory support platform including the TandemHeart, TandemLung, and the ProtekDuo and ProtekSolo lines of cannulae.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings